HOSPITAL OF THE UNIV OF PENNA
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $2.9B
- Transactions
- 26,968
- Companies
- 40
- Average per transaction
- $106,708
Who reported the payments
| Biontech SE | $2,323,417,247 |
| Amicus Therapeutics, Inc. | $83,086,752 |
| Merck | $42,128,192 |
| Gilead | $34,051,382 |
| Janssen Research & Development, LLC | $27,198,929 |
| Pfizer | $19,809,572 |
| E.r. Squibb & Sons, L.L.C. | $19,279,671 |
| Biogen | $19,137,679 |
| Genentech, Inc. | $17,962,850 |
| Incyte Corporation | $17,156,462 |
| AstraZeneca | $15,809,999 |
| Novartis | $14,308,104 |
| Eli Lilly | $14,075,535 |
| Amgen | $10,708,659 |
| AbbVie | $9,472,158 |
| Regeneron | $8,827,616 |
| Spark Therapeutics, Inc. | $8,613,747 |
| Amryt Pharma Holdings Ltd | $8,003,526 |
| Aegerion Pharmaceuticals, Inc. | $7,776,854 |
| Edwards Lifesciences | $6,573,674 |
| Siemens Medical Solutions USA, Inc. | $6,551,662 |
| CSL Behring | $6,476,092 |
| Bristol Myers Squibb | $5,986,040 |
| Chiesi USA, Inc. | $5,525,389 |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,402,688 |
| Janssen Scientific Affairs, LLC | $4,794,749 |
| Mallinckrodt Hospital Products Inc. | $4,457,046 |
| Seagen Inc. | $4,400,022 |
| Boehringer Ingelheim | $3,990,577 |
| Medtronic | $3,508,686 |
| Eisai Inc. | $3,125,673 |
| Johnson & Johnson | $2,980,462 |
| Medical Device Business Services, Inc. | $2,945,630 |
| Abbott | $2,841,617 |
| Varian Medical Systems, Inc. | $2,736,061 |
| Sanofi US Services Inc. | $2,676,272 |
| Boston Scientific | $2,613,335 |
| Alnylam Pharmaceuticals Inc. | $2,359,292 |
| Sanofi | $2,249,239 |
| Guerbet LLC | $2,097,748 |